Antech™ Expands Vector-Borne Disease Portfolio with Enhanced Accuplex™ and Most Comprehensive PCR Panel to Date
Based on current testing data disseminated by the Companion Animal Parasite Council (CAPC), Antech scientists estimate that tens of millions of dogs in North America are not tested for exposure to CVBDs annually. As cases of canine heartworm disease and tick-borne pathogens continue to rise in both endemic and emerging regions, Antech is committed to expanded care for dogs being exposed to these serious diseases.
Enhanced Accuplex can now detect antibodies to three Ehrlichia species, and two Anaplasma species, alongside heartworm (Dirofilaria immitis) antigen, and antibodies to confirm exposure to Lyme borreliosis (Borrelia burgdorferi). With the rising prevalence of tick-borne diseases across North America, this expanded detection capability ensures broader coverage and greater confidence in diagnostic results, ultimately supporting informed clinical decision-making.
Antech is also offering a new enhanced vector-borne disease PCR panel for dogs and cats to ensure veterinarians have comprehensive diagnostic offerings to meet emerging disease risks. While the traditional 'big four' vector-borne diseases (heartworm, Lyme borreliosis, anaplasmosis, and ehrlichiosis) remain the most diagnosed in North America, rising cases and increased geographical spread of Rocky Mountain spotted fever, babesiosis, cytauxzoonosis, and others demand wider flexibility in testing. Antech's enhanced vector-borne disease PCR panel is unique in the industry in providing veterinarians with the most comprehensive array of vector-borne pathogens in the veterinary industry to date.
The launch of enhanced Accuplex and the comprehensive vector-borne disease PCR panel follows the March 2025 announcement of Antech's new patient-side vector-borne disease screening test, trūRapid™ FOUR, a lateral flow test using whole blood, serum, or plasma to detect heartworm antigen and the complete suite of tick-borne antibodies encompassed in the enhanced Accuplex reference lab offering.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare's Science & Diagnostics division and Antech, said: 'Today, we celebrate our capability to offer veterinarians the flexibility to screen for these life-threatening vector-borne diseases with a complete portfolio of reference lab and in-house diagnostic offerings, meaning no other lab matches Antech in the breadth and depth of parasite and vector-borne diseases screening. The addition of two new Ehrlichia markers and one new Anaplasma marker to our Accuplex reference lab platform, as well as the launch of our PCR panel, will help ensure we can test more comprehensively for exposure to the most common vector-borne pathogens in North America.'
For more information, please visit antechdiagnostics.com.
Notes to editors
Key Features of enhanced Accuplex include:
Expanded Pathogen Detection: Accuplex now detects three Ehrlichia species and two Anaplasma species, increasing test sensitivity and allowing broader vector-borne disease screening across more regions.
Reference Lab Testing: Ensures reproducibility and reduces variability with highly trained technicians performing each assay.
Peace of Mind: Provides reliable and precise testing, fostering confidence among veterinarians and pet owners alike.
Key Features of enhanced Vector-Borne Disease PCR include:
Broader pathogen detection: This panel detects more vector-borne pathogens giving clinicians the best opportunity to identify the underlying cause of illness.
PCR vs. serology: While antibody production can lag behind infection, PCR is often the better choice for when VBD is suspected but not confirmed. It's also highly valuable when serology may miss early infection.
Common yet overlapping clinical signs: Vector-borne diseases frequently present with nonspecific or overlapping signs; improved PCR helps clarify these complex cases.
Resistance marker: The panel includes a new resistance marker, specifically detecting atovaquone resistance - a growing concern in the treatment of Babesia and Cytauxzoon infections. This supports responsible antimicrobial use and better-informed treatment decisions.
Antech at AVMA
Visit Antech at the AVMA Convention 2025 and the 40th World Veterinary Association Congress which will take place July 18-22, 2025 in Washington, D.C. to find out more about our vector-borne disease portfolio and to speak to a sales representative.
About Antech
Antech is a global veterinary diagnostics company, driven by our passion for innovation that helps veterinarians deliver better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Flatiron Health Announces Research to Be Presented at IASLC 2025 World Conference on Lung Cancer Hosted by the International Association for the Study of Lung Cancer
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced eight abstracts leveraging its high-quality multimodal data have been accepted for poster presentation and e-Poster presentation at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain. Our research at this year's WCLC exemplifies how high-quality, multimodal real-world data combined with responsible AI practices can illuminate treatment patterns, measure effectiveness, and reveal where innovation is most urgently needed. Share 'AI is a transformative force enabling scale, speed, and novel insights that were previously impossible. By harnessing advanced AI across our global network of more than five million people with cancer, we're setting a new standard for real-world data at scale,' said Nathan Hubbard, Chief Business Officer, Flatiron Health. 'Our research at this year's World Conference on Lung Cancer exemplifies how high-quality, multimodal real-world data combined with responsible AI practices can illuminate treatment patterns, measure effectiveness, and reveal where innovation is most urgently needed.' A highlight of Flatiron's presence at WCLC 2025 is the first published research leveraging the Flatiron Health–Caris Life Sciences Clinical-Molecular Database (CMDB), the largest and most robust multimodal dataset of its kind, to identify a novel gene signature that predicts risk of liver metastasis in patients with advanced non-small cell lung cancer (NSCLC). By integrating high-quality clinical data with comprehensive molecular profiling, the research addresses a critical unmet need—providing clinicians with a new tool to identify high-risk patients and potentially enable more personalized surveillance and treatment strategies. Additional highlights include: a poster highlighting ongoing gaps in biomarker testing after assessing over 13,000 patients with NSCLC in the US and UK a poster providing new insights into how NSCLC is managed in the UK, including details on the most commonly used treatments, patterns in biomarker testing, and overall survival outcomes Schedule a meeting with Flatiron Health at WCLC 2025 and follow Flatiron Health on X and LinkedIn for more updates from #WCLC25. Abstracts and Poster Presentations Partner: Caris Life Sciences Poster Session: P2.06 - Pathology and Biomarkers Presentation Number: P2.06.45 Location: Exhibit Hall Session Start/End: Monday, September 8, 10:30AM - 12PM Poster Session: P1.07 - Early-Stage Non-small Cell Lung Cancer Presentation Number: P1.07.05 Location: Exhibit Hall Session Start/End: September 7, 10:30AM - 12PM Poster Session: P3.13 - Small Cell Lung Cancer and Neuroendocrine Tumors Presentation Number: P3.13.10 Location: Exhibit Hall Session Start/End: September 9, 10 - 11:30AM Partners: Bristol-Myers Squibb, University of Colorado Cancer Center E-poster Session: EP.12 - Metastatic Non-small Cell Lung Cancer – Targeted Therapy Presentation Number: EP.12.23 Partners: Montefiore Medical Center, GSK, Rush University E-poster Session: EP.13 - Small Cell Lung Cancer and Neuroendocrine Tumors Presentation Number: EP.13.25 Partners: Lilly E-poster Session: EP.17 - Global Health, Health Services, and Health Economics Presentation Number: EP.17.33 Partners: Merck & Co E-poster Session: EP.13 - Small Cell Lung Cancer and Neuroendocrine Tumors Presentation Number: EP.13.44 About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Business Wire
3 hours ago
- Business Wire
Bardavon Launches Online Physical Medicine Portal Benefiting Claims Adjusters and Nurse Case Managers
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Bardavon is proud to announce the launch of Link, a new digital portal designed specifically for Adjusters and Nurse Case Managers (NCMs). This platform brings clarity, efficiency, and actionable insight to the forefront of injury case management and physical rehabilitation. Link is a one-stop online destination that gives Adjusters and NCMs 24/7 access to the information they need, when they need it. Key features of Link include: At-a-glance case summaries including actual visit counts, estimated case duration, and authorized visits remaining Snapshot views of patient case status such as current risk level, no-shows, care gaps, and reauthorization needs Easy access to view and download all case notes, updated nightly and viewable in-line with the patient record Comprehensive case details including appointments, attendance, predictive analytics, and open items requiring action Quality oversight includes clinical team case interventions for treating therapist and alerts to stakeholders regarding case progression All information is refreshed nightly to ensure timely and accurate updates. With Link, Bardavon takes information that was previously provided to Adjusters and NCMs incrementally via e-mail or fax and now presents it in an easily digestible and meaningful manner to generate actionable insights. Link is built on the same platform that Bardavon's clinical oversight team uses every day, effectively providing Adjusters and NCMs the same 360 degree case management view as Bardavon's clinical oversight staff. 'We're excited to roll out the Link online portal as part of our commitment to building tools and workflow guides focused on supporting Adjusters and Nurse Case Managers, with the hope of supercharging their workflow,' said Jen Henry, VP of Clinical Operations and Services at Bardavon. 'Link empowers our partners to proactively manage cases, access critical insights, and take timely action to keep care on track. Most importantly, it allows them to manage cases on their time, with the certainty of complete and consolidated case information.' Why Link? The name reflects the portal's core purpose: linking stakeholders to timely, relevant information, in turn fostering stronger collaboration, better communication, and accelerated case progression. Over time, Link will evolve to include additional features such as one-click access to submit new referrals and re-authorizations, visibility to the status of new referrals, and more. Built on the same platform as Bardavon's clinical coaching portal, Link pulls from the same prioritized clinical and administrative data set, providing Adjusters and NCMs the information they need, accessible when they want it. Bardavon recognizes that every adjuster and case manager works differently—which is why Link will never be mandatory. We pride ourselves on listening to our clients and making sure communication and reporting preferences can be tailored at the individual user level, whether that means using Link or continuing to receive notes and case-level details via email or fax. And just like other Bardavon program enhancements, such as Recovery+, there is no charge or fee associated with Link. "Ultimately, we see the release of Link as a natural extension of our commitment to developing tools that make the jobs of Nurse Case Managers and Adjusters easier, better, and more straight-forward,' said Sarah Meyer, Chief Operating Officer at Bardavon. 'Our focus is on meeting each end user where they are—adapting to their preferred workflow and timing, so they can work in the way that suits them best." To learn more about the Link portal, visit Bardavon is a nationwide network of PT/OT providers treating workplace injuries while focusing on the unique needs of each injured worker and their return-to-work goals. Our high-touch, tech-enabled service enhances and simplifies the patient management experience for each stakeholder, including payers, adjusters, case managers, and injured workers. This optimizes claims outcomes and reduces costs. To learn more, visit
Business Wire
3 hours ago
- Business Wire
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint of endoscopic response in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC). 'We are very disappointed that our study did not meet its efficacy endpoints, and our greatest regret is that people living with inflammatory bowel disease will not, for now, have the opportunity to benefit from a new treatment option,' said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. 'The gut microbiome is a well-recognized driver of IBD, yet remains a facet of the disease untouched by current treatments. As a field, we have not yet succeeded in making a meaningful impact for people with IBD through microbiome-based approaches, but every study moves us closer to that goal. We are committed to sharing further analyses of this study at upcoming scientific meetings to help chart new paths forward.' 'Our priority at Vedanta remains the successful execution of our ongoing global pivotal study of VE303 for the prevention of recurrent C. difficile infection, with the goal of potentially delivering the first approved Live Biotherapeutic Product in any indication — and, in doing so, addressing a serious health condition with a significant unmet medical need,' concluded Dr. Olle. In the randomized, placebo-controlled COLLECTiVE202 study, endoscopic and clinical responses were assessed using standardized criteria, and the observed response rates in the VE202 group were not statistically different from those in the placebo group. VE202 was generally safe and well tolerated — most adverse events were mild or moderate in intensity, with no reports of treatment-related serious adverse events. Analyses of bacterial colonization, histological findings, and immune responses are ongoing and will be shared in future scientific forums. Vedanta remains focused on advancing its other pipeline programs: VE303: Vedanta is currently enrolling patients into RESTORATiVE303, a registrational Phase 3 study of VE303 for the prevention of recurrent C. difficile infection (rCDI) at over 200 sites in 24 countries. The Phase 3 program is supported by results from a positive Phase 2 study, in which VE303 demonstrated potentially best-in-disease efficacy with a 30.5% absolute risk reduction compared with placebo and greater than 80% reduction in the odds of a CDI recurrence. VE707: Vedanta is also advancing VE707 to prevent infections by multidrug-resistant organisms that affect a wide range of vulnerable populations in areas such as oncology, urology, transplantation, and critical care, with IND submission planned for 1H 2026. About the COLLECTiVE202 Study COLLECTiVE202 is a double-blind, placebo-controlled, randomized clinical trial conducted at sites in the United States, Europe, and Australia. The study enrolled 114 patients, between the ages of 18 and 75 years, with mild-to-moderate ulcerative colitis who had not been exposed to any biologic or advanced oral therapies. Either VE202 (N=57) or placebo (N=57) was added to a patient's stable background ulcerative colitis therapy. The primary endpoints were safety and Week 8 endoscopic response (defined as a reduction of at least 1 point on the Mayo endoscopic subscore). Secondary endpoints included clinical response and remission, endoscopic improvement and remission, as well as histological assessments and measures of colonization, quality-of-life and inflammatory biomarkers. For more information on COLLECTiVE202 (NCT05370885), visit About Vedanta Biosciences Vedanta Biosciences is a clinical-stage biopharmaceutical company developing microbiome-based oral medicines for the treatment of gastrointestinal diseases. The company's lead asset is a potential first-in-class therapy, VE303, currently in a global Phase 3 registrational trial for prevention of recurrent C. difficile infection. Vedanta leverages its proprietary industry-leading product engine to develop therapeutic drug candidates based on defined bacterial consortia. The product engine is supported by broad foundational intellectual property and spans the development lifecycle from discovery to commercialization. It includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale.
